132,143 Shares in Repligen Co. (NASDAQ:RGEN) Purchased by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 132,143 shares of the biotechnology company’s stock, valued at approximately $19,021,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in RGEN. UMB Bank n.a. raised its stake in shares of Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares during the period. Oppenheimer & Co. Inc. purchased a new position in Repligen during the 4th quarter valued at about $216,000. Worldquant Millennium Advisors LLC increased its position in shares of Repligen by 11.9% during the third quarter. Worldquant Millennium Advisors LLC now owns 50,276 shares of the biotechnology company’s stock valued at $7,482,000 after buying an additional 5,337 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Repligen by 1.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 363,379 shares of the biotechnology company’s stock valued at $54,078,000 after acquiring an additional 5,478 shares during the period. Finally, Van ECK Associates Corp boosted its position in shares of Repligen by 7.8% in the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock valued at $6,078,000 after acquiring an additional 3,066 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on RGEN. HC Wainwright reissued a “buy” rating and issued a $180.00 price target on shares of Repligen in a report on Friday, February 21st. Royal Bank of Canada lifted their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. Canaccord Genuity Group began coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Canaccord Genuity Group raised their price target on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. lifted their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Repligen currently has a consensus rating of “Hold” and an average price target of $178.64.

Repligen Trading Down 2.2 %

Shares of RGEN opened at $141.95 on Wednesday. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $187.25. The firm has a market cap of $7.97 billion, a price-to-earnings ratio of -278.33, a PEG ratio of 4.54 and a beta of 0.95. The firm has a 50 day moving average price of $155.62 and a 200-day moving average price of $148.36. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. As a group, equities research analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax acquired 250 shares of the stock in a transaction dated Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.